The Great Strides Together program is a 1-day multi facility represented and planned meeting that includes continuing medical education credits designed for oncology physicians, nurses, nurse practitioners, physician assistants, residents and fellows, as well as other healthcare professionals involved in the management of cancer patients. The Great Strides Together program is well established in the state of Florida. Based on evaluations from the previous 10 consecutive years, this meeting has been able to deliver a state-of-the-art educational experience with an added theme of Team and hence, provide healthcare professionals with the tools to offer the best quality of care to their patients. The overall theme of this conference is Team and how the physician and the support staff work together to provide the best care for the patient. When possible, we ask that the sessions be presented together with the physician, Advanced Provider Professional, and if possible a nurse. We believe it is important to include in each presentation how the physician and team work together and the benefits this provides to all.
Dr. Winston Tan from Mayo Clinic Florida developed the educational initiative, Rapid Integration Course for PAs and NPs in Hematology/Oncology. Dr. Tan recognized that APPs are increasingly an important component of the oncology practice. Every year there are new practitioners that enter the practice without a systemic orientation course that would allow basic, practical and rapid integration into Florida practices. His mission was to develop a course that will include teaching basic skills that are important for a new practitioner in an hematology-oncology practice that will lead to rapid integration into the oncology workforce.
Rapid Integration Agenda
The following have registered to exhibit during this event. Thank you for supporting FLASCO events!
Adaptive Biotechnologies Alexion Pharmaceuticals Amgen Oncology Astellas Oncology AstraZeneca Bristol-Myers Squibb Celgene EHRC Technologies EUSA Pharma Foundation Medicine Genentech Gilead Sciences Incyte Jazz Pharmaceuticals Merck Novartis Oncology Pfizer Oncology Sanofi Genzyme Takeda Oncology TEVA Oncology
Continuing Education Information
Evaluation and Certificate of Attendance
In order to receive CME/CE/CPE credits for this program:
- You MUST sign in at the registration desk.
- A link to the evaluation will be emailed to you post-program. Please complete this within the allotted time frame. If you do not receive a post-program email by 5/24/19, reach out to the FLASCO office.
- Your certificate of attendance will be emailed to you for download immediately after submission. Please keep this document in your files.
Accreditation and Credit Statements
In support of improving patient care, the Medical Educator Consortium is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician – The Medical Educator Consortium designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing – The Medical Educator Consortium designates this activity for 11.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. ONCC review is only for designating content to be used for ILNA points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Physician Assistant – The Medical Educator Consortium has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 11.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Disclosure Policy – The Medical Educator Consortium (MEC) adheres to the Joint Accreditation Criteria and ACCME Standards for Commercial Support, which requires everyone in a position of controlling the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests related to the activity content. MEC has implemented a mechanism to identify and resolve all conflicts of interest prior to the CME/CE activity being delivered to learners. The source of all support from commercial interests will also be disclosed to learners prior to the beginning of the educational activity. CME/CE activities must be balanced, independent of commercial bias, and designed to improve quality in health care. All recommendations involving clinical medicine must be based on evidence within the medical profession.
Disclosure of Unlabeled Use – This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contradictions, and warnings.
Disclaimer – Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contradictions and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
GREAT STRIDES TOGETHER
CART-T Cell Therapy – Krishna Komanduri, MD
Peptide Receptor Radionuclide Therapy (PRRT) – Pashtoon Kasi, MD and Ashton Ritter, PA-C
Immunotherapy: Treating Lung Cancer and the Importance of Lung Cancer Screening – Gelenis Domingo, MD and Paola Izquierdo, APRN
Post Transplant Management of Chronic Side Effects – Asmita Mishra, MD and Marian Dam, DNP, APRN
FLASCO: Why you should belong and What is the role of the APP? – Winston Tan, MD, FACP
Radiation Treatment: Pharmaceutical Aspects – Ana Botero, MD and Radiation Treatment: Pharmaceutical – Kimberly McDuffie, APRN, FNP-BC
Molecular Therapy – Martin Dietrich, MD
Clinical Trials – MaryBeth Molloy, PA-C
Multiple Myeloma – Beth Faiman, PhD, MSN, APRN-BC, AOCN and Chakra Chaulagain, MD, FACP
RAPID INTEGRATION COURSE
Answering the Why and What I need to know – Winston Tan, MD, FACP
Communication: Empathy and how to give bad news – Ana Rosa Espinosa, DNP, MBA, RN, OCN
How to manage bleeding and clotting – Steven Fein, MD
Dr. Fein Heme Handout – Steven Fein, MD
Clinical Pearls for the New Advanced Provider – Jessica McMillan, DNP, FNP, ARNP-BC
Pharmacology 101: Mechanism and targets in medical oncology – Lindsay Williamson, ARNP, MSN, AOCNP
Basics of Billing and Coding & Understanding Prior Authorizations – Rachel Rutledge